Shifting Perspectives R33 Phase: Enhancing Outcomes in Anorexia Nervosa With CRT
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05017831 |
Recruitment Status :
Recruiting
First Posted : August 24, 2021
Last Update Posted : January 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anorexia Nervosa | Behavioral: Family Based Treatment Behavioral: Cognitive Remediation Therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 96 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | Random assignment to one of two groups. |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Any study team member who is assessing for outcomes will not know which participant/family is in which group. |
Primary Purpose: | Treatment |
Official Title: | Shifting Perspectives R33 Phase: Enhancing Outcomes in Adolescent Anorexia Nervosa With Cognitive Remediation Therapy (CRT) |
Actual Study Start Date : | November 5, 2021 |
Estimated Primary Completion Date : | August 15, 2024 |
Estimated Study Completion Date : | August 15, 2024 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Family Based Treatment (FBT)
Families will receive 15 sessions of FBT alone.
|
Behavioral: Family Based Treatment
Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
Other Name: FBT |
Experimental: FBT w/ Adolescent-focused Cognitive Remediation Therapy
Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of FBT over six months. The first 9 sessions of FBT will be preceded by adolescent-focused CRT.
|
Behavioral: Family Based Treatment
Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
Other Name: FBT Behavioral: Cognitive Remediation Therapy Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
Other Name: CRT |
- Change in executive functioning [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will use the Delis Kaplan Executive Functioning System (D-KEFS ) Trails Number-Letter Sequencing subtest, a neurocognitive behavioral task, to assess ability to set-shift (a core component of executive functioning). Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better executive functioning.
- Change in response inhibition [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will use the Delis Kaplan Executive Functioning System Inhibition subtest, neurocognitive behavioral task, to assess ability to inhibit automatic responses. Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better response inhibition.
- Change in set-shifting [ Time Frame: Baseline, during treatment, end of treatment ]Also using the Delis Kaplan Executive Functioning System Inhibition task, investigators will use scores from the D-KEFS Inhibition/Switching subtest to assess ability to switch between alternating rules (a component of set shifting). Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better set-shifting.
- Change in shifting accuracy [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will use the Delis Kaplan Executive Functioning System Verbal Fluency subtest, neurocognitive behavioral task, to assess accuracy in shifting categories (a component of executive functioning). Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better shifting accuracy.
- Change in category switching flexibility [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will also use the Delis Kaplan Executive Functioning System Verbal Fluency subtest, category switching scores, to assess flexible switching (a component of executive functioning). Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better switching flexibility.
- Change in flexibility [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will use the Delis Kaplan Executive Functioning System Sorting subtest, neurocognitive behavioral task, to assess changes in flexibility.Investigators will compare change in scaled scores from pre, during, and post-treatment across groups. Scaled scores range from 0-19 with higher scores indicating better flexibility.
- Change in self-reported inhibition control [ Time Frame: Baseline, during treatment, end of treatment ]The Behavior Rating Inventory of Executive Functioning is a self and parent-report measure of executive functioning. The measure comprises 10 clinical scales, of which investigators will use the Inhibition subscale to assess self-reported inhibition control (ranged from 0-100, with higher reporting greater set-shifting ability). Investigators will compare change in T scores from pre, during, and post-treatment across groups.
- Change in self-reported set-shifting [ Time Frame: Baseline, during treatment, end of treatment ]The Behavior Rating Inventory of Executive Functioning is a self and parent-report measure of executive functioning. The measure comprises 10 clinical scales, of which investigators will use the Shifting subscale to assess self-reported set-shifting. Investigators will compare change in T scores (ranged from 0-100, with higher reporting greater set-shifting ability) from pre, during, and post-treatment across groups.
- Rate of weight gain [ Time Frame: Baseline, during treatment, end of treatment ]Investigators will weigh participants during treatment to compare rate of change (slope) in weight gain from pre, during, and post-treatment across groups. Larger change in weight indicates greater recovery from the eating disorder.
- Change in eating disorder symptomology [ Time Frame: Baseline, during treatment, end of treatment ]Adolescents will complete the Eating Disorder Examination - Questionnaire (a 28-item self-report measure of eating disorders symptomatology), while parents will complete the Anorectic Behavior Observation Scale (a 30-item collateral report measure of eating and exercise behavior). Investigators will examine changes in these scores from baseline, during, and post-treatment. Scores range from 0-6 with higher scores suggesting more severe eating disorder symptomatology.
- Change in behavioral flexibility (amount consumed) [ Time Frame: Baseline, during treatment, end of treatment ]Adolescents will complete a buffet meal during which investigators will record the amount of food they consume in grams. This task aims to assess changes in behavioral flexibility by objectively assessing food choice in individuals with an eating disorder. Investigators will examine changes from baseline, during, and at treatment completion. A larger amount of food eaten (in grams) represents greater behavioral flexibility.
- Change in behavioral flexibility (eating disorder behaviors) [ Time Frame: Baseline, during treatment, end of treatment ]Adolescents will complete a buffet meal during which investigators will record eating behaviors using a novel checklist (a total score of eating disorder behaviors observed). These behaviors include staring, fidgeting, inappropriate napkin use, frequency of food tearing, frequency of dissecting food. Minimum score for this variable is 0, however, there is no maximum frequency. This task aims to assess changes in behavioral flexibility by objectively assessing eating-related behaviors in individuals with an eating disorder, with higher scores suggesting lower behavioral flexibility. Investigators will examine changes from baseline, during, and at treatment completion.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: Adolescents
- Age 12-18
- Currently meets Diagnostic and Statistical Manual-5 criteria for Anorexia Nervosa
- Medically stable for outpatient treatment
- Fluent in English
- No co-morbid condition that would exclude participation
- Medical clearance from primary care physician and permission to speak to Primary Care Physician about clinical issues
- Biological parent or primary caregiver willing to engage in treatment and who lives with the adolescent
Inclusion Criteria: Parents
- Age >18
- Child with a diagnoses of AN
- Parent or caregiver willing to participate
- Fluent in English
- No co-morbid condition that would exclude participation
Exclusion Criteria: Adolescents
- Adolescent outside age range
- Pregnant adolescent
- Presence of: pervasive developmental disability, psychosis, bipolar disorder, substance abuse, autism spectrum disorder, or intellectual disability
- Presence of: a brain disorder or injury (such as TBI) that could impact the ability to engage in treatment
- Use of anti-psychotic medication
- Concurrent psychosocial therapy
Exclusion Criteria: Parents
- Presence of: pervasive developmental disability, psychosis, uncontrolled bipolar disorder, substance abuse, autism spectrum disorder, or intellectual disability.
- Presence of: a brain disorder or injury (such as TBI) that could impact the ability to engage in treatment
- Use of anti-psychotic medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05017831
Contact: Catherine Alix Timko, PhD | 267-426-5467 | timkoc@chop.edu | |
Contact: Amanda Makara, BS | 267-425-1321 | makaraa@chop.edu |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | Recruiting |
Philadelphia, Pennsylvania, United States, 19146 | |
Contact: Catherine Alix Timko, PhD 267-426-5467 timkoc@chop.edu | |
Contact: Amanda Makara, BS 267-425-1321 makaraa@chop.edu | |
Principal Investigator: Catherine Alix Timko, PhD |
Principal Investigator: | Catherine Alix Timko, PhD | Children's Hospital of Philadelphia |
Responsible Party: | Children's Hospital of Philadelphia |
ClinicalTrials.gov Identifier: | NCT05017831 |
Other Study ID Numbers: |
21-019079 5R61MH119262-02 ( U.S. NIH Grant/Contract ) |
First Posted: | August 24, 2021 Key Record Dates |
Last Update Posted: | January 6, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Anorexia Anorexia Nervosa Signs and Symptoms, Digestive Feeding and Eating Disorders Mental Disorders |